G
GT Biopharma, Inc. (GTBP)
NCM – Real Time Price. Currency in USD
0.43
+0.01 (3.34%)
At close: Jun 26, 2026, 4:00 PM EDT
0.44
+0.01 (1.35%)
After-hours: Jun 26, 2026, 7:53 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
0.43
+0.01 (3.34%)
At close: Jun 26, 2026, 4:00 PM EDT
0.44
+0.01 (1.35%)
After-hours: Jun 26, 2026, 7:53 PM EDT
No Data
There are no news for this stock.
Cash reserves $9.0M barely cover the upcoming debt maturities $0.0
Total current assets $9.4M exceed Total current liabilities $2.4M, highlighting excellent liquidity
Debt-to-equity ratio (0.0) is near the industry average, reflecting balanced leverage
Interest coverage ratio (-45.2x) is dangerously low, suggesting debt repayment risks
Negative free cash flow -$2.5M limits the company's ability to reinvest or pay down debt
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 3.90 | 6.05 | 10 | |
| Quick ratio | 3.90 | 5.63 | 10 | |
| Debt to Equity | 0.00 | 0.30 | 10 | |
| Debt to Assets | 0.00 | 1.04 | 10 | |
| Interest coverage | -45.21 | -16.91 | 1.0 | |
| Weighted average score | 8.2 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Operating Income | -21M | -14M | -14M | -12M | -13M |
| Net Income | -21M | -8M | -13M | -28M | -48M |
| EBITDA | -21M | -14M | -14M | -12M | -13M |
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Gross margin % | N/A | -11.73 | 1.0 | |
| Operating margin % | N/A | -24.60 | 1.0 | |
| Net margin % | N/A | -172.20 | 1.0 | |
| EBITDA margin % | N/A | -201.27 | 1.0 | |
| Cash flow margin % | N/A | -156.39 | 1.0 | |
| Weighted average score | 1.0 | |||
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | N/A | 85.45 | 5.5 |
| Next quarter | N/A | 90.36 | 5.5 |
| Current year | N/A | 94.91 | 5.5 |
| Next year | N/A | 20.59 | 5.5 |
| Weighted average score | 5.5 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 999 | 87.7 | 95.05 | 38.62 | 10 |
| Y/Y | 999 | -265.07 | 66.67 | -12.07 | 5.5 |
| 3y average | 999 | -41.67 | N/A | -1.32 | 3.3 |
| 5y average | 999 | -33.2 | 46.59 | -23.27 | 5.5 |
| Weighted average score | 6.1 | ||||
Insufficient positive free cash flow for DCF analysis
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
Insufficient positive free cash flow for DCF analysis
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |